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Public Participation in Decision-Making on the Coverage of New 
Antivirals for Hepatitis C 
 
Abstract 
 
Purpose 
New hepatitis C medicines such as sofosbuvir underline the need to balance 
considerations of innovation, clinical evidence, budget impact and equity in health 
priority-setting. This article examines the role of public participation in addressing 
these considerations.  
 
Design/Methodology/Approach 
The article employs a comparative case study approach. It explores the experience of 
four countries–Brazil, England, South Korea and the USA–in making coverage 
decisions about the antiviral sofosbuvir and involving the public and patients in these 
decision-making processes. 
 
Findings 
Issues emerging from public participation activities include the role of the universal 
right to health in Brazil, the balance between innovation and budget impact in 
England, the effect of unethical medical practices on public perception in South 
Korea, and the legitimacy of priority-setting processes in the USA. Providing 
policymakers are receptive to these issues, public participation activities may be re-
conceptualized as processes that illuminate policy problems relevant to a particular 
context, thereby promoting an agenda-setting role for the public. 
 
Originality/Value 
The article offers an empirical analysis of public involvement in the case of 
sofosbuvir, where the relevant considerations that bear on priority-setting decisions 
have been particularly stark. The perspectives that emerge suggest that public 
participation contributes to raising attention to issues that need to be addressed by 
policymakers. Public participation activities can thus contribute to setting policy 
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agendas, even if that is not their explicit purpose. However, the actualization of this 
contribution is contingent on the receptiveness of policymakers. 
 
Keywords 
Hepatitis C, direct-acting antivirals (DAAs), sofosbuvir, public and patient 
involvement (PPI), priority-setting, agenda-setting 
 
Article Classification 
Case Study 
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Introduction 
 
In 2013 the Food and Drug Administration (FDA) in the United States of 
America (USA) approved sofosbuvir and simeprevir for the treatment of chronic 
hepatitis C infections (FDA, 2014). The regulatory agencies of other countries soon 
followed and the use of sofosbuvir was approved by the European Medicines Agency 
(EMA) in January 2014 (EMA, 2015). These medicines, along with a third called 
daclatasvir, were hailed as a breakthrough in the treatment of patients with chronic 
hepatitis C as they are considered to be highly effective antiviral agents that, for the 
first time, attack the hepatitis C virus (HCV) directly. These drugs are not only more 
effective in achieving sustained virological response–effectively curing patients–but 
also have fewer side effects than previous treatments. Unsurprisingly, there has been 
high demand for these new “cures” for hepatitis C among patients–especially given 
the alternative prospects of deteriorating liver function and possible liver 
transplantation or death, alongside the psychological distress and social stigma 
attached to the disease (Vietri et al, 2013; Younossi and Henry, 2015). 
However, the new HCV medicines come at a price. It is a price that most 
countries struggle to afford, regardless of their wealth or the structure of their health 
system. The actual price of the regimen is hard to unveil because many health care 
systems engage in confidential negotiations with pharmaceutical manufacturers for 
discounted prices, but a 12-week treatment with sofosbuvir has been estimated to cost 
as much as $84,000 in the USA (McCarthy, 2015). Policymakers or insurers face 
difficult decisions on whether to cover these novel and costly medicines, weighing the 
benefits these drugs could offer against the opportunity costs of securing health 
benefits for the broader population. Such challenges raise questions about what role, 
if any, patients and the public have in priority-setting decisions for new and expensive 
drugs. This article outlines how the highly innovative, but very expensive, new 
hepatitis C medicines have exacerbated the challenge of making prioritization 
decisions in health care and explores the role of patient and public involvement (PPI) 
in addressing this challenge. 
The focus of the article arises from deliberations held at a workshop at the 
Brocher Foundation in Switzerland in November 2015. The workshop was dedicated 
to exploring ways to improve equitable access to health care through increasing 
public and patient involvement in prioritization decisions. It brought together 
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academic and policy experts in health priority-setting and public involvement from 12 
countries. Its purpose was to exchange knowledge and observations about country 
experiences of PPI in priority-setting. One of the observations emerging from the 
deliberations was that the new HCV medicines seem to have exacerbated the 
challenge of making fair prioritization decisions because of the complex set of issues 
around innovation, clinical evidence and budget impact to which they give rise. This 
article asks what role, if any, public involvement has played in alleviating some of 
these issues. How have countries involved the public and patients in addressing the 
question of how to secure equitable access to new hepatitis C medicines? What can 
we learn from this experience? 
In the extant literature, the importance of involving the public in health 
priority-setting is explained with reference to the complex and multiple relevant 
considerations that can bear on decisions. For example, to justify the model of 
“accountability for reasonableness”, Daniels and Sabin (1997) argue that priority-
setting institutions must ensur  fair processes. Because more than one relevant 
consideration generally bears on priority-setting questions, relevant considerations 
often conflict and there is no consensus among decision-makers, commentators or the 
public at large as to how to trade them off against each other. Daniels and Sabin give 
PPI a role in ensuring fair process and many commentators argue that it should take 
center-stage (Emanuel, 2002; Friedman, 2008; Rid, 2009; Sabik and Lie, 2008). 
This article contributes to the existing debates by offering an empirical 
analysis of public involvement in the case of sofosbuvir, where the relevant 
considerations that bear on priority-setting decisions have been particularly stark. It 
examines how the public has been involved in decisions on new HCV medicines in 
four countries (Brazil, England, South Korea and the USA), thereby offering 
comparative insights on how different health systems involve the public in complex 
priority-setting problems, and on the perspectives that emerge. Perspectives that 
emerge include the role of the universal right to health in Brazil, the balance between 
innovation and budget impact in England, the effect of unethical medical practices on 
public perception in South Korea, and the legitimacy of priority-setting processes in 
the USA. Although these issues are contextual and not necessarily novel in the 
individual contexts, they appear more pronounced in the case of sofosbuvir. If 
policymakers are aware of, and receptive to, these issues, public participation 
activities may be usefully re-conceptualized as processes that illuminate salient policy 
Page 4 of 26Journal of Health Organization and Management
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
 5 
problems relevant to a particular context, thereby supporting an agenda-setting role 
for the public. The actualization of this role is highly contingent on policymakers 
being receptive to the issues. Given the important perspectives that emerged in the 
case of sofosbuvir, this article concludes that further research is necessary on whether 
they have found traction in the public policy arenas of Brazil, England, South Korea 
and the USA.  
The article proceeds by providing a brief conceptual overview of health 
priority-setting and PPI, the methods and data for the case studies, the new HCV 
medicines generally, and of sofosbuvir particularly. These sections set the scene for 
the discussions of the country case studies and the conclusion in the latter parts of the 
article. 
 
Health Priority-Setting and Patient and Public Involvement  
 
Setting priorities in health care holds a prominent place on the policy agenda 
in countries around the world, particularly as countries seek to achieve universal 
health coverage. The advent of this agenda, including the creation of health 
technology assessment (HTA) organizations, has brought about an increased interest 
in the role of PPI in health prioritization (e.g. Martin et al., 2002; Abelson et al., 
2007) because decisions involve making difficult choices that cannot be made solely 
on technical grounds and hence need to be justified and legitimized in the context of 
social values and procedural justice (Clark and Weale, 2012; Daniels and Sabin, 
1997).  
Regardless of where priority-setting takes place, it is concerned with making 
decisions that provide a good quality, and a fair, health service while ensuring that the 
health system is sustainable. The extant literature suggests that public input into the 
choices made should be included as one important criterion against which to assess 
the fairness of prioritization decisions (Sibbald et al., 2009; Kapiriri and Martin, 2010; 
Sabik and Lie, 2008). However, barriers to public involvement exist (Goold et al., 
2005) and little empirical evidence is available on the effect of PPI generally, and 
different modes of PPI such as deliberative processes specifically (Mitton et al., 2009; 
Abelson et al., 2003).  
This article follows Weale et al.’s (2016, p. 5) definition of public 
participation in priority-setting as involving “[…] individuals or groups taking part in 
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processes of policy making that shape the determination of priorities in health care 
and the conditions of access of different groups in society”. It is collectively-
orientated and excludes forms of patient involvement such as involvement in research 
or shared decision-making as these forms of involvement are not aimed at bringing 
about a decision that affects public policy at large. This collectively-orientated mode 
of public participation can come in different forms such as the inclusion of patient or 
public representatives in HTA bodies, mini-publics or consultative forums convened 
to garner public and patient views. Importantly, it also includes more unconventional 
forms of public participation such as protests, demonstrations, public campaigns and 
litigation. To include these forms of involvement is crucial because in some countries 
they have become a routinized mode of involvement that can affect priority-setting 
decisions (Weale et al., 2016; Slutsky et al., 2016). 
 
Methods and Data 
 
The article employs a comparative case study approach. Its main units of 
analysis are the country-specific processes of public participation in the case of 
sofosbuvir. We focus on sofosbuvir because it has received substantial attention in 
media outlets worldwide. The country case selection was informed by the aim to 
include countries with conventional and unconventional modes of public participation 
in health prioritization (Weale et al., 2016). For reasons of data availability, the 
selection was restricted to the countries represented at the Brocher Foundation 
workshop entitled “Improving equitable access to health care through patient and 
public involvement in prioritization decisions” in Switzerland in November 2015. The 
represented countries were Australia, Brazil, China, Colombia, Germany, New 
Zealand, South Africa, South Korea, Sri Lanka, Thailand, the United Kingdom (UK) 
and the United States of America (USA). 
Following Slutsky’s et al.’s (2016) distinction between consensus, i.e. 
conventional, and contestatory participation, i.e. unconventional, modes of 
participation, Brazil, England, South Korea and the USA were selected as cases. 
England represents a system where contestatory participation is not routinized 
(Slutsky et al., 2016), whereas Brazil and South Korea represent countries where it is 
routinized. The USA represent a unique case in that participation is neither clearly 
consensus nor contestatory-based because of a lack of federal prioritization decision-
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making in which the public participates in a routine fashion. Nevertheless, as we shall 
see, forums for participation do exist in the form of institutes such as the Institute for 
Clinical and Economic Review (ICER).  
The article draws on country data on PPI and health priority-setting that was 
presented at the Brocher Foundation workshop. This data was supplemented by data 
from secondary literature. At the workshop policy and academic experts presented the 
status quo of health priority-setting and PPI in their countries following a template of 
nine areas (see http://www.ucl.ac.uk/socialvalues for presentations):  
1) Overview of health system and approaches to prioritization; 
2) Degree and nature of PPI in prioritization; 
3) Rationale for PPI; 
4) Successes and challenges; 
5) A prioritization case study and impact of PPI in this case; 
6) Issues highlighted by the case study; 
7) Ethical or social values questions in relation to PPI; 
8) Lessons learnt;  
9) Future plans for PPI in prioritization.  
  
In its discussion of the country cases, this article broadly follows the outlined 
template. Each case study begins with a brief overview of the health system and 
approaches to PPI in health prioritization. A discussion of the rationale as well as the 
successes and challenges of PPI is omitted because the focus is on the prioritization 
case study (sofosbuvir) and the issues, ethical questions and lessons learnt. Unless 
they emerge directly from PPI in the case of sofosbuvir, the category of future plans 
for PPI is also omitted for the purpose of this paper.  
 Due to the small number of cases included in this article, the generalizability 
of the observations is limited. However, the purpose of this article is not to bring forth 
generalizable claims, but to provide an insight into the role PPI has played in 
coverage decisions on new HCV medicines. This is to gain a better understanding of 
the contributions of PPI activities in complex prioritization decisions.  
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New HCV medicines 
 
“Hepatitis C is a virus that can infect the liver” (NHS Choices, 2015). Long-
term, and potentially life-threatening complications from chronic hepatitis C infection 
include liver cirrhosis and liver cancer. More than 185 million people are affected by 
hepatitis C and approximately 350,000 people die each year as a consequence (WHO, 
2014, p. 25). Hepatitis C is transmitted through contact with infected blood specimens 
(WHO, 2014). There are several types and subtypes of the infection, so-called 
genotypes. 
 In recent years a rapid development in treatments for chronic hepatitis C has 
taken place. In 2011 and 2012 the medicines telaprevir and boceprevir were 
introduced. Since 2013 additional medicines have been approved around the world, 
namely sofosbuvir, simeprevir and daclatasvir. These medicines are direct-acting 
antivirals (DAAs) that target the HCV itself, an innovation over previous treatments 
that indirectly suppressed the virus through inhibiting its replication.  
 This article focuses on sofosbuvir. The main clinical endpoint measured in 
randomized controlled trials (RCTs) on hepatitis C medicines is the sustained 
virological response (SVR), that is the virus being undetectable in the blood three or 
six months after treatment (WHO, 2014). Sofosbuvir achieved a SVR in over 90% of 
the patients across different genotypes of hepatitis C (WHO, 2014). Clinical experts 
equate the achievement of a SVR to a cure (NICE, 2015, p. 46). Arguably, providing 
a drug like sofosbuvir would not only yield benefits for patients, but also avert future 
high costs associated with liver transplants as well as generate public health benefits 
through reduced HCV transmission. However, there is still much uncertainty 
surrounding the potential of future (liver) complications for patients who have cleared 
the virus or the question of which patients would progress to more serious stages of 
liver disease if left untreated. Trials on sofosbuvir report fewer, and less severe, side 
effects as well as a potential reduction of the treatment cycle from 24-48 weeks to as 
little as 12 weeks (WHO, 2014). Additionally, sofosbuvir is administered orally in the 
form of a pill once a day for usually 12 weeks, whereas previous methods of 
administration were mostly through injections.  
 However, at an estimated price of $84,000 for a 12-week treatment in the 
USA, sofosbuvir has been labeled the $1,000 pill (McCarthy, 2015). The first WHO 
guidelines on the screening, care and treatment of patients with hepatitis C 
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 9 
recommend access to the new medicines. In the absence of sufficient funds to treat the 
entire patient population, they recommend to treat the sickest patients first (WHO, 
2014). This is the way a number of countries have approached the access, for example 
guidelines in the USA and England recommend to treat patients with cirrhosis first 
(McCarthy, 2014; NICE 2015).  
The challenge of providing access to these new medicines includes 
considerations of cost effectiveness, affordability, health equity, public health and the 
ethical implications of treating the sickest patients first. One of the biggest issues is 
how to resolve the perceived tension between cost effectiveness and affordability. The 
approach to prioritization in many tax-based health systems focuses on the assessment 
of cost effectiveness, with an assumption - explicit or implicit - that treatments should 
be made available to all patients for whom they deliver outcomes whose cost 
effectiveness exceeds a pre-determined threshold. But when the total budget impact of 
such a treatment is large, its adoption may require significant re-direction of 
resources, either from other areas of health spending, and/or from areas of non-health 
expenditure (Claxton et al., 2015; Ward, 2015). A re-direction of resources raises 
questions of equity with regard to the patient groups who lose out as a result. It 
therefore requires debate and resolution in the political space, which may or may not 
include the wider public.  
The above issues are complicated by the fact that Hepatitis C is already 
strongly associated with health inequities. It disproportionately affects populations in 
low and middle income countries (Graham and Swan, 2015), which to date have not 
had much access to available treatments due to the challenging screening and 
monitoring requirements. Moreover, sofosbuvir and other DAAs have been labeled a 
cure, a label that few other medical innovations achieve. Familiar issues of pricing 
and the current patent system are also surfacing. For example Argentina, Brazil, 
China, Russia and the Ukraine are challenging the current patent for the new hepatitis 
C drugs (Bagcchi, 2015). Similarly, a non-governmental organization of doctors in 
France that provides healthcare for vulnerable populations worldwide, the Médecins 
du Monde, is challenging the patent at the European Patent Office (EPO) (Boseley, 
2015). Given this mix of complex issues, the question arises if PPI can help 
adjudicate between the different issues. What has the experience of involving the 
public and patients been in the case of sofosbuvir?  
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Public Participation in the Case of Sofosbuvir 
 
Brazil 
 
The Brazilian Public Health System, better known by the acronym SUS 
(Sistema Único de Saúde; Unified Health System) was established under the Federal 
Constitution of Brazil in 1988. Enshrined in the Constitution is a right to health care 
and a governmental duty to guarantee universal and equal access to services and 
activities that promote, protect and restore health (Paim et al., 2011). Brazil’s forums 
for public participation include municipal and state health councils comprised of 
members of the public and patient representatives. Through these councils health care 
planners are held to account by the citizenry (Dall’Agnol Modesto et al., 2007). 
Brazil’s tradition of public involvement is also reflected in the way the public is 
involved in the SUS. The National Health Council, which consists of a mix of 
representatives of service user organizations (50%), health care worker 
representatives (25%), government and health service providers (25%), holds monthly 
meetings in which proposals are deliberated (Dall’Agnol Modesto et al., 2007).  
In the case of sofosbuvir, the National Commission on Technology 
Incorporation in the National Health System (CONITEC), the HTA body in Brazil, 
decided unanimously to recommend the inclusion of sofosbuvir, daclatasvir and 
simeprevir for the treatment of chronic HCV (CONITEC, 2015). The 
recommendation was preceded by a public consultation on HTA report. Public 
contributions were made through submissions to the CONITEC website. 
During the process of assessing sofosbuvir, CONITEC also presented revised 
Clinical Protocol and Therapeutic Guidelines (PCDT) for the disease, with new 
guidance on treating the condition. The assessment process did not evoke as much 
public protest and engagement as did the revised PCDT. According to the revised 
protocol, the degree of fibrosis determines the group of patients who are eligible to be 
treated with the new antiviral agents under the SUS, excluding patients at fibrosis 
stages F1 and F2 (PCDT, 2015).  
The Brazilian Movement of the Fight against Viral Hepatitis voiced its 
dissatisfaction with the protocol and invoked the constitutional universal right to 
health, claiming that the patient groups included in the protocol “represent less than 
4% of the current need and means tearing the principle of universality of access to 
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health”1 (MBHV, 2015). The official estimate is that 60,000 patients will be treated 
with sofosbuvir in the next two years. To the Work Group of Intellectual Property 
(GTPI), “this is less than 1/3 of the related demand […]” (GTPI, 2015).  
 The fact that the Brazilian Movement of the Fight against Viral Hepatitis 
invoked the constitutional universal right to health reflects a prominent feature of 
many health systems in Latin America where the right to health is enshrined in the 
Constitution. Reimbursement decisions on medicines are made through benefit plan 
assessments (BPA), following the principles of financial sustainability and of clinical 
efficiency. For a molecule to be considered for BPA, it generally has to overcome the 
HTA hurdle. In order to ensure financial sustainability some countries perform 
different degrees of Budget Impact Analysis (BIA) (e.g. Ministerio de Salud de 
Colombia, 2015). In this setting there is an inherent tension between the HTA results 
and the BPA results that may yield that a cost effective technology is unaffordable for 
the entire system, which is why CONITEC recommended restricting access to 
sofosbuvir according to fibrosis stage. 
Given the constitutional protection of the right to health, Latin American 
individuals and campaign groups can resort to courts to challenge the results of the 
HTA and BPA. Every year thousands of Latin Americans resort to this 
unconventional form of PPI and more often than not judges rule in favor of the 
avalanche of plaintiffs (Cubillos et al., 2012). The effect that easy litigation has on the 
incentives to participate in the more established PPI mechanisms is unclear. If one can 
almost certainly win a case in less than two weeks, why join a process that may take 
months or years and that may not lead to your desired outcome? Policymakers in 
Latin America continue to grapple with the constraining effects of the constitutional 
right to health on priority-setting decisions.   
 
England 
  
 The National Health System (NHS) is a tax-based health system in which 
national and local structures share decision-making responsibility. At local level, 211 
clinical commissioning groups (CCGs) are responsible for commissioning (Thorlby 
and Arora, 2014), i.e. buying, health services from public, private or non-profit health 
                                                        
1
 Translated by one of the authors of this article. 
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care providers. At the national level, NHS England oversees spending and allocation 
of resources (NHS England, 2016). CCGs and NHS England are supported by the 
National Institute for Health and Care Excellence (NICE), an organization responsible 
for appraising the clinical and cost effectiveness of new medicines. If NICE makes a 
positive recommendation on a new drug, then commissioners are under a legal 
obligation to make the treatment available (NICE, 2016). NICE makes its appraisals 
on the basis of clinical and cost effectiveness considerations as well as social value 
judgements (Rid et al., 2015).  
 NICE conducts a public consultation process for every treatment it appraises. 
In this process there are two groups that are allowed to participate, namely consultees 
and commentators. Consultees include patient and professional organizations, the 
pharmaceutical manufacturer, government and NHS entities (NICE, 2013, p. 4). 
Commentators include manufacturers of comparator technologies or research groups 
who are allowed to comment, but do not have a right to appeal the decision. The 
wider public can submit comments on NICE’s website (NICE, 2016a). 
 NICE made a positive recommendation for the use of sofosbuvir, although the 
use of sofosbuvir in genotypes 4, 5 and 6 was only recommended in patients whose 
infection had already progressed to liver cirrhosis (NICE, 2015). The contentious 
issues did not arise as a result of NICE’s appraisal of sofosbuvir, but as a result of 
NICE’s decision to grant NHS England an extension to the normal implementation 
period in which a NICE-recommended treatment has to be made available on the 
NHS. Usually NHS commissioners have to ensure that patients receive access to the 
recommended treatment within three months after it has been recommended (NICE, 
2016). In the case of sofosbuvir a waiver of this period was sought by NHS England 
(NICE, 2014a). Four reasons were provided: First, NHS England argued that the 
health service had to be reworked in order to provide access to the new medicines 
through specialized treatment centers. Second, a substantial increase in demand for 
treatment could be expected, making it necessary for NHS England to ensure it could 
accommodate this demand. Third and fourth, networks for service provision would 
have to be created in order to guarantee that appropriate screening and monitoring 
structures were in place for hepatitis C patients (NICE, 2014a).  
 Although NHS England’s request downplayed the expected budget impact of 
sofosbuvir as a reason for the request–because budget impact is not an eligible reason 
for such extensions under the legal framework set by the government–the ensuing 
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protest suggests that stakeholders agreed that it was a veiled request based on 
concerns about budget impact (NICE, 2014b). The submissions by NHS England 
suggest that such views were not far-fetched. According to NHS England’s 
submission: “[…] at the prices proposed by the manufacturer in their NICE 
submission, this technology is not affordable at the quantum of new expenditure it 
would represent” (NICE, 2014, p. 8). Consultees were given the opportunity to 
comment on NHS England’s request. One patient organization summarized the 
problems as follows: 
The Hepatitis C Trust objects in the strongest possible terms to any attempt to 
introduce budget as a factor. If we are going to change our health care 
resource allocation model to one based on arbitrary consideration of this 
year’s budget, then this should be debated nationally, preferably through an 
election manifesto. Either NICE has a mandate to decide resource allocation 
or it doesn’t (The Hepatitis C Trust, 2014, p. 6).  
 
 The submissions in response to NHS England’s request to delay the date by 
which sofosbuvir has to be made accessible highlights complex questions about the 
how the ability of NICE’s decision-making framework to accommodate cost 
effectiveness and affordability is perceived by stakeholders. The patient 
representatives raised the issue that if budget impact is an implicit consideration in 
cases such as sofosbuvir, then this has to be made explicit and deserves debate in the 
wider public and political policymaking arena.  
 
South Korea 
 
 The Republic of Korea has a National Health Insurance Service (NHIS) that 
covers 96.6% of the population (OECD, 2012). The rest of the population is covered 
“[…] by a medical aid plan which is directly funded by […] the national and local 
governments […]” (Ahn, 2012, p. 344). While the NHIS is known for its population-
based universal coverage, the benefits that are covered are limited and out-of-pocket 
payments were at 36.9% in 2013 (OECD, 2015) even though the benefit coverage has 
expanded since the 1990s. 
In 2012 the NHIS set up a lay citizen’s council, the Citizen Committee for 
Participation, made up of lay members of the public who are selected following an 
application process. Although still in its early years, the decision-making mechanism 
of the Committee, and its influence on the final decisions by the Health Insurance 
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Policy Committee (HIPC), are considered significant. In its first year 69% of newly 
covered services were originally chosen and recommended by the Citizen Committee 
(Oh et al., 2015). However, except for the Citizen Committee, PPI is not prominent in 
Korea unless a nationwide interest develops that puts pressures on adopting new 
health technologies, especially pharmaceuticals. Such was the case with sofosbuvir.  
The case of sofosbuvir reached the public agenda not through the Citizen 
Committee, but through a scandal that rocked a clinic in Seoul in November 2015. 
Sofosbuvir was approved by the regulatory authority in September 2015 (MFDS, 
2015). A scandal arose in a neighborhood in Seoul when an outbreak of HCV was 
tied to the re-use of disposable needles at a local clinic specializing in intravenous 
(IV) injection services (Ah-young, 2015). According to the Korea Times (Ah-young, 
2015a), a total of 78 HCV infections were confirmed until the fourth of December 
2015 and 55 out of 78 patients were found to have type 1a, which is usually prevalent 
in less than 1% of the hepatitis C patients in Korea (Seong et al., 2013). Many 
Koreans learned about the dis ase and the treatment option of sofosbuvir and its 
combination drug from news reporting on a massive scale and they were sympathetic 
to the victims of unethical medical practices. The incident elevated the issue of 
sofosbuvir to the national political arena, with public and advocacy groups 
campaigning for access to the new medicines. The coincidence of this event and the 
reimbursement review process of these drugs finally resulted in the Ministry of Health 
and Welfare asking for a faster review of sofosbuvir (The DailyPharm, 2015).  
The Korean experience highlights additional ethical issues that characterize 
the debate on new hepatitis C drugs, namely issues of fairness, government 
accountability and public responsibility when infections occur due to unsafe medical 
practices. This is the case in the recent scandal in Korea, but similar examples can be 
found in other countries, for example in the UK where contaminated blood 
transfusions in the 1980s led to increased HCV infections. Even though this issue did 
not emerge as a result of formalized PPI processes, the public outcry in Korea 
underlines the effectiveness of public campaigns in the face of such scandals. The 
final reimbursement decision is outstanding at the time of writing, but given the 
scandal and the ensuing public reaction, it is unlikely that the formalized PPI process, 
if pursued by the decision-making authorities, will lead to any recommendation other 
than to reimburse sofosbuvir.  
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The USA: The Institute for Clinical and Economic Review 
 
Due to the fragmented nature of the American health care system there is no 
one government-mandated institution for health priority-setting. Following the 
introduction of the Patient Protection and Affordable Care Act in 2010, the health 
care system remains a predominantly private system but the percentage of uninsured 
continues to drop (The Commonwealth Fund, 2015). There are two publicly 
subsidized and federally managed health care programmes, namely Medicare for the 
elderly population over 65 and Medicaid for families meeting low-income eligibility 
criteria (The Commonwealth Fund, 2015). Given the lack of institutionalized priority-
setting, this section examines the experience of an independent research body, the 
Institute for Clinical and Economic Review (ICER)2, that produces evidence reports 
on new medicines, on which payer organizations such as insurers draw.  
 The Institute for Clinical and Economic Review is an independent research 
institute funded largely by non-profit foundations. It produces evidence reports on 
medical technologies to help guide the application of evidence to clinical practice and 
insurance coverage policy (ICER, 2014). The Institute has created 
regional committees of independent clinicians and public representatives, called 
Comparative Effectiveness Public Advisory Councils (CEPAC), who are convened to 
deliberate on evidence reports in meetings open to the public (ICER, 2016).  The 
meetings are spent debating the evidence, after which the CEPAC votes on whether 
the evidence is adequate to demonstrate that a new technology is as good or better 
than other options available to patients. The reports include evidence on cost 
effectiveness and potential budget impact and the Institute asks the CEPAC groups to 
vote on the "value" of new interventions. 
The Institute’s draft evidence report on the HCV medicines received criticism 
from patient advocacy groups focused predominantly on the results of the economic 
analyses that found that these drugs would not reduce long-term costs in the health 
care system while presenting huge potential short-term costs that could overwhelm 
health care budgets (ICER, 2014a). At the public CEPAC meeting, the CEPAC voted 
that the evidence was adequate to demonstrate the clinical superiority of the new 
                                                        
2
 In order to avoid confusion between the incremental cost effectiveness ratio (ICER) and the 
Institute for Clinical and Economic Review (also ICER), this article does not use the ‘ICER’ 
abbreviation for the Institute, but refers to it as the ‘Institute’ or spells out its full name. 
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drugs but that they represented a "low" value to the health care system3  (ICER, 
2014b). The voting stage of the meeting was followed by a so-called policy 
roundtable, an invited group composed of representatives from insurers, 
manufacturers, clinical experts and patients. The roundtable included the leader of one 
of the patient groups. This representative criticised the vote of the CEPAC and sought 
to cast aspersions on the clinical expertise, primary motives, and financial interests of 
all involved (ICER, 2014c).  The clinical experts responded by expressing their belief 
that, for clinical and economic reasons, the most reasonable path forward was to 
prioritize patients for treatment, with sicker patients receiving treatment first (ICER, 
2014c). They felt this was reasonable not only because the short-term clinical risks 
were minimal, but because there was inadequate infrastructure to treat all patients 
immediately and because the financial repercussions of immediate treatment for all 
eligible patients was unrealistic (ICER, 2014c).   
The recommendation to use severity of initial liver damage as a method of 
prioritizing patients was the recommendation that was included in the final CEPAC 
report (ICER, 2014). The patient advocacy organizations did not accept this 
recommendation and opposed it in the press (Clary, 2015). But private and 
public health insurers felt empowered to establish their initial coverage 
recommendations to mirror this approach, and many cited the CEPAC report as 
justification (e.g. UnitedHealthcare, 2014).  Anecdotally, many insurers informed the 
Institute that having a transparent, independent process for evidence review was 
important to their decision-making. Even if patient advocacy groups disagreed with 
the result, insurers felt that the overall process had enough legitimacy to serve as a 
cornerstone of their coverage policies. 
The case underlines complex questions about the purpose of PPI and the 
legitimacy of prioritization decisions. While insurers found the Institute’s process 
helpful, the protests by patient advocacy groups suggest that they did not view the 
CEPAC vote as a fair outcome of a legitimate process. The extant literature on the 
legitimacy of decision-making processes in health priority-setting converges on the 
idea that outcomes of decisions are more legitimate if the public has been involved 
(Daniels and Sabin, 1997; Abelson et al., 2007; Parkinson, 2003). However, the 
                                                        
3
 Please note that this section is an account from one of the co-authors who is the Director of 
the Institute and was present in the deliberations. The full summary of the proceedings can be 
found on the Institute’s website (ICER, 2015). 
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experience of the Institute for Clinical and Economic Review in the case of HCV 
medicines suggests that enhancing the legitimacy of decision-making processes of 
independent review bodies in the eyes of public and patient representatives remains a 
challenging issue. 
 
Discussion and Conclusion 
 
Examining PPI in the case of sofosbuvir across multiple and diverse settings 
highlights that none of the countries included in this paper diverted from their 
established modes of involving the public and patients. These modes need to be 
viewed in the political and historical contexts of the respective countries. They led to 
different, yet very important, questions that need to be addressed. In England, 
stakeholders stressed the controversies that arise when cost effective medicines are 
not covered within the statutory timeframe due to budget impact concerns, even 
though such a delay is statutorily permitted in certain circumstances. This suggests 
that the methodological approach employed by NICE does not sit easily with 
stakeholders. The public consultation process highlighted this issue, but it cannot be 
resolved in the currently available PPI forums. It is a political question that needs to 
be addressed in the wider public space.  
In South Korea, a scandal pre-empted potential deliberations by the 
established Citizen Committee of Participation. The Korean example brings to the 
forefront the importance of what Slutsky et al. (2016) label ‘contestatory 
participation’ and of the significant pressure that media campaigns can exert on 
decision-making in health priority-setting. It remains to be seen how the story 
unfolds, but it seems likely that the established forums of PPI will not deviate from 
the public perception that the novel HCV medicines should be made available in the 
light of unethical medical practices. The Korean example is as much a story of 
successful pressure exerted through media spaces as it is an example of how an issue 
can reach the policy agenda and exacerbate the challenges faced by policymakers. 
The experiences of the USA and Brazil countries underline the importance of 
national context. The deliberative meetings held by the Institute for Clinical and 
Economic Review fill a void in a fragmented health system in which insurers, the 
public and patient advocacy groups have little guidance on which to draw when 
making tough decisions or engaging with each other. The Institute’s experience 
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accentuates the role that deliberative processes can play in evaluating evidence. 
However, it also shows how challenging it is for these processes to be viewed as 
legitimate by all those involved (Kieslich and Littlejohns, 2015), and failing to 
establish legitimacy is a real barrier to the contribution that public participation 
activities can make. In Latin America, PPI takes places in the context of national 
health systems that guarantee a right to health. The public and the patients insist on 
their right to health and policymakers are faced with the constraints that this system 
puts on policies that seek to introduce efficiency savings. 
In conclusion, has the PPI experience in Brazil, England, South Korea and the 
USA helped address some of the difficult challenges that arise in the case of 
sofosbuvir? The short answer is no. The country experiences are as much a tale of 
challenges that arise when making difficult prioritization decisions as they are a tale 
of agenda-setting. With regard to the unconventional modes of participation such as 
protests and litigation, this observation is not surprising as they tend to receive much 
attention in the media. Howev r, with regard to the more conventional modes of 
participation through consultation and deliberation, this observation is interesting as it 
may suggest an agenda-setting role for the public even when this is not the explicit 
purpose of these modes of participation. PPI on sofosbuvir has brought a number of 
issues to, or back on, the policy agenda. In England, policymakers need to address 
what NICE’s cost effective paradigm implies for a cash-strapped NHS. The American 
experience suggests it may be time for policymakers to think about how they can help 
insurers and providers establish decision-making processes that are perceived as 
legitimate by the public. In South Korea, the importance of combining ethical and 
budgetary considerations has been underlined, especially when patients are infected 
with HCV through no fault of their own. In Latin America policymakers are having to 
strike the balance between realizing the right to health and the necessity to ensure the 
sustainability of health care systems (Ferraz, 2011). Of course, whether these issues 
find traction on the policy agenda depends on the receptiveness and willingness of 
policymakers to engage with them, and this question is an area for further research. 
The possible role of issue characteristics (Lowi, 1964; Burgin, 1995) also 
merits attention in future research. Lowi (1964) argues that variations in policy-
making processes can be explained with reference to the character and type of issues 
that are being addressed. In the case of pharmaceutical products issue characteristics 
include the disease area, the population affected, cost effectiveness, budget impact 
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and questions of equity. The question that demands further exploration is whether 
certain characteristics of issues brought forth by cases such as the new HCV 
medicines call for a stronger, or a particular mode of public involvement. Given its 
large budget impact, views from the wider public could be gained on the kind of 
trade-offs they would be willing to make if access to the new hepatitis C medicines is 
to be provided. However, constructing a case for a stronger, or a particular mode of 
public involvement, will rest on the resolution of at least three arguments against it.   
First, the discussed issues are not new or unique to HCV medicines. They are 
simply more pronounced in this case. The novel HCV drugs have brought to light the 
challenging issues that have long concerned policymakers, practitioners and 
academics. To use these challenges as an argument for going beyond existing modes 
of PPI would run the risk of establishing a case of exceptionality that may not be 
justified. Second, existing modes of involvement or participation all come with their 
own advantages, disadvantages and risks (Weale et al., 2016). Regardless of how 
carefully a particular mode of involvement is chosen, chances are that none of them 
can address the entire breadth of issues. Third, isolating the situations in which issue 
characteristics exacerbate the challenges of decision-making to such an extent that 
warrants for taking the issues to the public at large would be difficult. Nevertheless, 
the complex trade-offs emerging in priority-setting decisions on HCV medicines 
suggest that the normative and empirical role of issue characteristics is worth 
exploring.  
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